Form 4: Enliven Therapeutics Director Gupta Rishi Acquires Stock Options

Director Gupta Rishi acquired stock options in Enliven Therapeutics, Inc. on February 6, 2025.

Summary

• On February 6, 2025, Rishi Gupta, a director and 10% owner of Enliven Therapeutics, Inc., acquired stock options to purchase 20,491 shares of common stock at an exercise price of $22.47.
• The options vest on the earlier of the first anniversary of the 2025 annual meeting or the date of the 2026 annual meeting, contingent upon Gupta's continued service as a non-employee director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of an insider transaction. The acquisition of options could be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon Gupta's continued service as a non-employee director, suggesting a commitment to the company.

Industry Context

Form 4 filings are routine disclosures of insider transactions and provide transparency to the market regarding the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a director.

Key Dates

Keywords

stock options, director, Gupta Rishi, Enliven Therapeutics, ELVN, beneficial ownership, Form 4, acquisition